KYNTRA BIO CEO buys 2,800 shares in open market

Rhea-AI Filing Summary

KYNTRA BIO, INC. CEO Thane Wettig reported an open-market purchase of common stock. He bought 2,800 shares on May 14, 2026 at a price of $7.09 per share, bringing his direct holdings to 27,203 shares. He also reports indirect ownership of 40 shares held by his spouse.

Insights

Equity compensation and insider-trading analyst

KYNTRA BIO’s CEO made a modest open-market share purchase.

CEO Thane Wettig purchased 2,800 shares of Common Stock at $7.09 per share in an open-market transaction. Following the trade, he directly owns 27,203 shares and reports an additional 40 shares indirectly through his spouse.

This is a straightforward insider buy with no derivatives or tax-related mechanics. The scale appears limited, and there is no indication of a pre-arranged trading plan in the excerpt. Overall, it looks like a routine, modest increase in his direct equity position.

Insider Trade Summary

Net Buyer: 2,800 shares

Net Buy 2 txns

Insider Wettig Thane

Role CEO

Bought 2,800 shs ($20K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,800	$7.09	$20K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 27,203 shares (Direct); Common Stock — 40 shares (Indirect, By spouse)

Key Figures

Shares purchased: 2,800 shares Purchase price: $7.09 per share Direct holdings after transaction: 27,203 shares +2 more

5 metrics

Shares purchased 2,800 shares Open-market purchase of Common Stock on May 14, 2026

Purchase price $7.09 per share Average price for CEO’s open-market purchase

Direct holdings after transaction 27,203 shares CEO’s direct Common Stock ownership following the purchase

Indirect holdings after transaction 40 shares Indirect Common Stock ownership reported as held by spouse

Net buy shares 2,800 shares Net buy volume per transaction summary

Key Terms

open-market purchase, Common Stock, indirect ownership, Form 4

4 terms

open-market purchase financial

"Purchase in open market or private transaction"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

indirect ownership financial

"ownership_type: "indirect" and nature_of_ownership: "By spouse""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KYNTRA BIO (KYNB) report for its CEO?

KYNTRA BIO CEO Thane Wettig reported buying 2,800 shares of Common Stock. The purchase was an open-market transaction dated May 14, 2026, and increased his direct ownership to 27,203 shares, plus 40 shares indirectly held through his spouse.

At what price did the KYNTRA BIO (KYNB) CEO buy shares in this Form 4?

The CEO bought KYNTRA BIO Common Stock at an average price of $7.09 per share. This open-market purchase involved 2,800 shares, resulting in a total cash outlay of roughly $19,852 before commissions or fees, based on the reported per-share price.

How many KYNTRA BIO (KYNB) shares does the CEO own after this transaction?

After the reported transaction, CEO Thane Wettig directly owns 27,203 shares of KYNTRA BIO Common Stock. The filing also shows 40 additional shares reported as indirectly owned through his spouse, reflecting a small separate holding attributed to family ownership.

Was the KYNTRA BIO (KYNB) CEO’s transaction an open-market purchase?

Yes. The Form 4 classifies the CEO’s transaction as an open-market purchase coded “P.” This means he bought 2,800 shares in the market, rather than receiving them as a grant, option exercise, or other non-market equity award mechanism.

Does the KYNTRA BIO (KYNB) Form 4 show any stock sales by the CEO?

No stock sales are reported for the CEO in this Form 4 excerpt. The transaction summary shows one open-market purchase totaling 2,800 shares, no sales, and no derivative exercises, indicating a net increase in his reported share ownership position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 08:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wettig Thane

(Last) (First) (Middle)

C/O KYNTRA BIO, INC.

350 BAY STREET, SUITE 100, #6009

(Street)

SAN FRANCISCO CALIFORNIA 94133

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KYNTRA BIO, INC. [ KYNB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		P		2,800	D	$7.09	27,203	D
Common Stock								40	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John Alden, Attorney-in-Fact	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)